DelMar Pharmaceuticals, Inc. | 2013 | FY | 3



  
Number of
warrants
  
Amount
$
 
       
Balance - December 31, 2011
  -   - 
         
Warrants issued for patents (i)
  500,000   89,432 
Warrants issued as unit issue costs (ii)
  105,000   14,295 
Warrants issued for services (iii)
  345,000   49,379 
         
Balance - December 31, 2012
  950,000   153,106 
Warrants issued as unit issue costs (iv)
  5,250,000   6,288,594 
Warrants exercised on a cashless basis (v)
  (200,000)  (239,600)
         
Balance - December 31, 2013
  6,000,000   6,202,100 
 
i)  
At December 31, 2011, the Company recognized the fair value of the 500,000 contingent Valent warrants (note 4). The contingent warrants were recognized in additional paid in capital at December 31, 2011 and have been reclassified to warrants when the warrants were issued on February 1, 2012. The warrants have an exercise price of CDN $0.50 per warrant and expire February 1, 2017.
 
ii)  
The Company has issued broker warrants as finder’s fees in relation to the issuance of certain units. All of the warrants were issued on March 1, 2012 and have an exercise price of CDN $0.50 per warrant. Of the total, 100,000 expire March 1, 2015 and 5,000 expire March 1, 2014.
 
iii)  
The Company has issued 345,000 warrants for investor relations services. The warrants were issued on February 1, 2012 and they vest in 12 equal installments over a 12-month period commencing on March 1, 2012. The warrants have an exercise price of CDN $0.50 per warrant and expire February 1, 2015.
 
iv)  
As part of the Company’s unit offering the Company has issued 5,250,000 Placement Agent Warrants (note 8(f)). The Placement Agent Warrants have been recognized as non-cash issue costs and the costs have been allocated to common stock and derivative liability. The portion allocated to additional paid in capital was $4,087,586 and the portion allocated to derivative liability was $2,201,008. The Placement Agent warrants have been valued using a simulated probability valuation model using the following assumptions:  dividend rate - 0%, volatility - 104%, risk free rate - 1.0% and a term of five years.
 
v)  
During the year ended December 31, 2013 200,000 Placement Agent Warrants were exercised on a cashless basis for 123,810 shares of common stock.

us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock